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Abstract
Intracellular dysfunction of the cystic fibrosis transmem-
brane conductance regulator (CFTR) has been proposed
to alter endosomal acidification. The most widely studied
consequence of this defect has been alterations in the bio-
chemical properties of cystic fibrosis (CF) respiratory mu-
cus glycoproteins. However, studies confirming the existence
of mucous processing defects in CF have been hindered by
the lack of in vivo animal models by which to test these
hypotheses in the absence of secondary effects of chronic
bacterial infection. The human bronchial xenograft model
has been useful in evaluating the pathophysiologic differ-
ences between CF and non-CF airway epithelium, in the
absence of secondary disease effects such as goblet cell hy-
perplasia. In this study we sought to compare the extent of
sulfation within secreted mucus glycoproteins from CF and
non-CF human bronchial xenografts. Cumulative results of
xenografts generated from 13 independent CF tissue sam-
ples demonstrated a statistically significant higher level of
sulfation (1.7+0.18, P < 0.026) as compared to non-CF
paired controls. Such findings add to the growing body of
knowledge that primary defects in sulfation exist in CF re-
spiratory mucin. Correlation of genotype with the extent of
mucus sulfation revealed two categories of CF tissues with
statistically different mucus sulfation profiles. Results from
these studies demonstrated a 2.0±0.15-fold higher level of
mucus sulfation produced from xenografts of five defined
CF genotypes as compared to non-CF controls (P < 0.004,
n = 10). Interestingly, three CF samples for which one
mutant allele remained undefined (AF508/unknown or
G551D/unknown) demonstrated no statistical difference in
the level of sulfation as compared with matched non-CF
controls (n = 3). This as yet unknown allele was not identi-
fied within a screen for the 26 most common CF mutations.
These results provide preliminary evidence for allelic varia-
tion within the CF population which may begin to elucidate
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the structure-function of CFTR with regards to intracellular
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Introduction
Cystic fibrosis (CF)' is a lethal inherited disease caused by
abnormalities in epithelial cell function (1, 2). Patients usually
die of respiratory failure due to recurrent and destructive pneu-
monia. The primary cellular abnormality in the lung is believed
to reside in the epithelium of the airways and submucosal
glands. Isolation of the gene responsible for CF has provided
insight into the molecular basis of the disease (3, 4, 5). Ongoing
progress in the development of effective gene therapies for CF
have shown tremendous promise. Despite successes in the abil-
ity to transfer the cystic fibrosis transmembrane conductance
regulator (CFTR) gene to lungs of animals models (6, 7, 8)
and the recent initiative of phase I clinical trials (9, 10, 11),
little is known about the underlying pathophysiologic mecha-
nisms which lead to the development of chronic bacterial infec-
tions and unavoidable morbidity of this lung disease. The identi-
fication of functionally relevant endpoints for evaluating the
effectiveness of gene therapy approaches will aid in the devel-
opment these therapeutic strategies.
Current hypotheses of the pathophysiologic mechanisms
which lead to the unusually thick mucus in CF and chronic
Pseudomonas infections are based primarily on the notion that
CF respiratory epithelia have defective chloride secretion and
elevated sodium absorption (12-15). Although the molecular
etiology of defective chloride secretion is known to be due
to lack of CFTR channel activity, mechanisms by which Na
absorption is elevated remain obscure. These alterations in elec-
trolyte transport are thought to create a milieu for bacterial
infection by decreasing epithelial fluid secretion which in turn
leads to improper hydration of mucus at the epithelial surface,
poor mucociliary clearance, and ultimately bacterial coloniza-
tion ( 1, 16). In addition to the contribution of electrolyte trans-
port, several other findings have suggested that primary defects
in mucous sulfation, sialylation, and/or glycosylation may also
contribute to the predisposition of bacterial colonization in the
CF lung (17-20). These findings suggest, that in addition to
apical chloride channel function, CFTR may also play an intra-
cellular role in the processing of glycoproteins. Several studies
have supported the notion that CFTR may act as an intracellular
1. Abbreviations used in this paper: CF, cystic fibrosis; CFTR, cystic
fibrosis transmembrane regulator.
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chloride channel which regulates anion transport, in conjunction
with an ATP driven proton pump, to acidify endosomal com-
partments (21, 22). These studies which analyzed the intrave-
sicular pH of golgi compartments have demonstrated a higher
pH in CF as compared with non-CF cells. Such defects in golgi
pH have been proposed to effect processing of glycoproteins
by shifting the pH of this compartment and decreasing the activ-
ity of modifying enzymes such as sialyltransferase. Other stud-
ies evaluating the effects of defective CFTR on endosomal recy-
cling also support the notion that, in addition to functioning at
the apical membrane, CFTR also plays an important role as an
intracellular chloride channel (23, 24).
Previous studies have attempted to evaluate the pathophysi-
ologic contribution CFTR may play as an intracellular chloride
channel by analyzing biochemical defects in CF mucus (25-
27). Two approaches have been traditionally used for this anal-
ysis including: (a) the purification and fractionation of mucus
from CF and non-CF patients followed by analysis of sulfate,
sialic acid, and carbohydrate composition (26, 27) and (b) the
purification and fractionation of radiolabeled mucus glycopro-
teins from CF and non-CF primary nasal or tracheal explants
(26, 28). Because of the complexity of mucus glycoprotein
modifications which accompany bacterial infection, disease
controls have been used in these studies to minimize the extent
of secondary effects. However, due to the unique nature of
bacterial infection in CF, secondary changes in mucous bio-
chemistry may likely differ from those found in diseased con-
trols such as chronic bronchitis. Researchers have attempted to
address this potential complication by in vitro analysis of nasal
and tracheal primary explants which have been removed from
the infectious milieu. However, even in the absence of active
bacterial infection in primary explants, this experimental design
also provides limitations due to the effects of surface epithelial
cell remodeling (i.e., goblet cell hyperplasia) which likely per-
sist in culture. Hence, in the absence of a genetic CF model not
complicated by bacterial infection or surface airway remodel-
ing, the elucidation of primary defects in mucus remain contro-
versial (29) as indicated by reports which show no abnormali-
ties in the biochemical properties CF mucus (30).
A uniquely suited model of the human CF and non-CF
airway epithelium called human bronchial xenografts has been
previously described (7, 31, 33). In this model system, a fully
differentiated epithelium is generated from primary cultures of
human bronchial airway epithelial cells seeded onto denuded
rat tracheas and transplanted into athymic mice. The ability
to reconstitute a fully differentiated epithelium from cultured
progenitor cells has allowed for the reconstruction of more pris-
tine CF airways free from secondary effects of bacterial infec-
tion. Recently, in vivo electrophysiologic evaluation of this
model system has characterized defects in chloride and Na trans-
port which are indicative of those seen in native CF nasal epithe-
lium (32). Using the human bronchial xenograft model, this
report attempts to evaluate the existence of sulfation defects
in respiratory mucus glycoproteins from seven different CF
genotypes. We compared the sulfation patterns of radiolabeled
large molecular weight mucin purified from thirteen CF and
non-CF paired human bronchial xenografts. This model system
has allowed for a more physiologic evaluation of primary de-
fects in CF mucous biochemistry which are free from secondary
effects of airway remodeling due to chronic bacterial infection.
Methods
Generation of CF and non-CF human bronchial primary cell cultures
and xenograft airways. Human bronchial xenografts were generated
from proximal bronchial tissue harvested from donor (non-CF) and
recipient (CF) lungs at the time of transplantation. 13 CF and non-CF
paired tissues were analyzed. The CF genotypes analyzed in this study
included AF508/AF508 (4); AF508/1717-lG-.A (2); AF508/
621+l G-*T (2); G542X/G551D (1); AF508/G542X (1); AF508/
unknown (2); and G55lD/unknown (1). The unknown CF alleles are
defined as the absence of the following 26 common mutations: G85E,
Rl 17H, 621+1G>T, R334W, R347C, R347P, R347H, S492F, Q493R,
1609delCA, A1507, AF508, 1717-lG>A, G542X, S549I, S549N,
S549R(A>C), G551D, R553X, R506T, R1162X, S1251N, W1282X,
R1283M, R1283K, and N1303K. This panel of mutations has detected
87% of 301 CF chromosomes analyzed from the University of Pennsyl-
vania Molecular Diagnostic laboratory. Of the 13 non-CF patients geno-
typed, one was heterozygous for the AF508 mutation. Primary cultures
of bronchial airway epithelial cells were prepared according to a previ-
ous protocol with modifications (31). Modifications in this protocol
were adopted to grow cells within a commercially available media
(BGEM; Clonetics Corp., San Diego, CA) which allows for the growth
of primary cells with basal cell characteristics (i.e., cytokeratin-14 posi-
tive by immunocytochemistry, data not shown). We felt that these
alteration would provide more homogeneous cultures from CF and non-
CF tissues and minimize the secondary effects carried over to primary
culture (i.e., the percentage of goblet cells). Additionally, culture me-
dium contained 80 ,g/ml tobramycin, 100 ,g/ml ceftazidime, 100 jig/
ml imepenam/cilastatin, and 2.5 ug/mI amphotericin B to control bacte-
rial and yeast infections. Cultures were propagated by two techniques
including explant growth (12-20 d in culture) and proteinase released
primary cells (4-7 d in culture). Both techniques provide similar results
with respect to the airway reconstitution of xenografts (data not shown).
Cultures were harvested by treatment of 0.1% trypsin followed by the
addition of 10% FCS/Ham's F12. Cells were pelleted and resuspended
in hormonally defined medium for seeding into denuded rat tracheas
generated by freeze thawing and irrigation three times. Denuded rat
tracheas are devoid of any viable airway epithelium and do not reconsti-
tute an epithelium when transplanted without seeded primary cells (data
not shown). Tracheas were ligated to flexible tubing at both ends after
seeding of 2 x 106 primary bronchial epithelial cells in 30 IL of hormon-
ally defined medium. Xenografts were implanted in pairs (one non-CF
and one CF) subcutaneously in the flanks of male nu/nu Balb/c mice
such that the ends of the tubing passed through the skin and were easily
accessible for flushing and harvesting of mucus. Xenografts were flushed
biweekly with Ham's F12 to remove excess mucus and other secreted
proteins. By week 3-4, grafts develop a fully differentiated mucociliary
epithelium. Mucin secreted from xenografts was metabolically labeled
as described below between 4 and 5 wk after transplantation.
Frequency of goblet cells in CF and non-CF xenografts. The per-
centage of goblet cells was evaluated by quantitating the number of
alcian blue positively stained cells in eight xenografts from four indepen-
dent genotypes of CF and non-CF paired xenografts. A total of > 5000
airway epithelial cells were screened from each xenograft to determine
the frequency of alcian blue positive goblet cells. Statistical comparisons
were performed using both paired and unpaired Student's t tests.
Isolation of metabolically labeled mucus glycoprotein from xeno-
grafts. Fully differentiated bronchial xenografts were metabolically la-
beled with both Na2S3504 (25 ACi) and [3H]glucosamine (25 MCi) for
72 h by instillation of radioisotope in Hepes-buffered phosphate ringers
(HPBR) solution. Metabolically labeled crude secretions were harvested
by irrigation with 1 ml of HPBR and frozen in dry ice. All analyses
were performed from paired CF and non-CF xenografts implanted in
the same mouse. Crude mucus secretions were purified by two rounds
of gel filtration by modifications of a previously described protocol (26,
28). Xenograft secretions were reduced and denatured by dialysis
against 10 mM Tris pH 8.0, 5 mM DTT, and 8 M urea for 24 h followed
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by fractionation in the same buffer on a sepharose CL-6B column ( 1
x 60 cm) at a flow rate of 1.5 ml/h. The void volume peaks were
pooled, carboxymethylated under nitrogen with 15 mM iodoacetamide
pH 9.0 for 45 min at 250C followed by extensive dialysis against 10
mM Tris pH 7.5, 50 mM NaCl, 1 mM PMSF for 48 h. Dialyzed sample
was mixed with concentrated stocks of NaAcetate, MgCl2, and PMSF
to a final concentration of 0.1 M NaAcetate pH 5.0, 3 mM MgCl2, 1
mM PMSF before digestion with 240 U/ml DNase and 75 U/ml of
bovine testicular hyaluronidase (Type VI; Sigma Chemical Co., St.
Louis, MO) for 6 h at 370C. This fraction was then dialyzed against 10
mM Tris pH 8.0, 5 mM DTT, and 8 M urea for 24 h followed by
centrifugation in a centricon-30. These concentrated samples (500 Al)
were loaded onto a second gel filtration Sepharose CL-6B column (2
x 125 cm) at a flow rate of 3 ml/h. Void volume peaks included
hyaluronidase insensitive mucus glycoprotein.
Additional enzymatic digestions of twice column purified hyaluroni-
dase insensitive large molecular mucin were performed with Chondroitin
ABC lyase and Heparin Lyase H to confirm the absence of sulfated
glycosaminoglycans in purified mucin fractions. Digestions with Chon-
droitin ABC lyase were performed by dialysis of purified mucin peaks
ha against 0.1 M Tris acetate buffer, pH 7.3 at 4°C followed by digestion
with 1 U/ml with Chondroitin ABC lyase (Sigma Chemical Co.) for
18 h at 37°C. Similarly digestion with Heparin lyase H (Sigma Chemical
Co.) were performed by dialysis of purified mucin peaks Ha against 0.1
M K2HP04, 1 mM CaCl2, pH 7.0 buffer at 4°C followed by digestion
with 1 U/ml Heparin lyase H for 18 h at 43°C. Digested mucin samples
were then dialyzed against 10 mM Tris pH 8.0, 5 mM DTT, 8 M
urea buffer and refractionated by CL-6B column chromatography. The
percentage of [3H]glucosamine and S31O4 in the void and included
volume fractions were compared with that of control samples digested
in the absence of enzyme. Since pilot studies with CF and non-CF
samples demonstrated the no change in the void volume elution profile
or the S "04/ [3H] glucosamine ratios of purified mucin fractions, these
digestions were not incorporated into the general purification scheme
used to analyze samples in this report.
Statistical analysis comparing the extent of sulfation between CF
and non-CF xenografts was performed using the Student's t test. Because
of variability in the absolute 35S and [3H]glucosamine labeling effi-
ciency between independent experiments performed on different days,
all comparisons were performed by a paired analysis of the raw 35S/
[3H] glucosamine ratios between CF and non-CF samples grafted in the
same mouse. Statistical significance denotes a P < 0.05.
Lectin binding studies to determine relative mannose and sialic acid
content. To confirm that purified mucin pools were separated from
mannose rich contaminating glycoproteins, we analyzed purified mucus
fractions for the extent of lectin specific binding to sialic acid and
mannose. Various fractions from the mucus glycoprotein purification
were normalized to 1000 total dpm of [3H]glucosamine label and slot
blotted onto nitrocellulose. After blocking of nitrocellulose filters with
a 1% lectin blocking solution (B & M) in 50 mM Tris pH 7.5 overnight
at 4°C, filters were probed with peroxidase-LFA lectin (for the detection
of sialic acid) or peroxidase-GNA lectin (for the detection of mannose)
for 4 h at room temp. Filters were then washed four times in 50 mM
Tris pH 7.5 and reacted with DAB substrate to visualize peroxidase
bound lectin. Typical reaction times were between 2-10 min. Purified
mucus glycoprotein standard (isolated from bovine submandibular
gland; Sigma Chemical Co.) was used to relate the intensity of staining
to known microgram quantities of mucus glycoprotein.
Results
Expansion ofairway progenitor cell in vitro removes secondary
effects ofgoblet cell hyperplasia in CF xenografts. The genera-
tion of in vivo bronchial xenograft airways from both CF and
non-CF tissues provides the unique opportunity to assess the
biochemical differences in secreted mucin from fully differenti-
ated airways. Since, previous studies evaluating secreted mucin
in CF airway explants have been hindered by secondary effects
of airway remodeling in the presence of bacterial infection, we
sought to generate a more pristine CF airway free from goblet
cell hyperplasia. We hypothesized that transplantation of bacte-
rial free cultured primary cells would allow for expansion of
airway progenitor cells and generation of CF airways with a
normal abundance of goblet cells. To this end we evaluated the
abundance of goblet cells in CF and non-CF xenografts by
alcian blue histochemical staining. These studies demonstrated
no statistical differences in the abundance of alcian blue positive
goblet cells in four CF (3.2±1.3%) and non-CF (3.6+1.2%)
paired xenografts analyzed. These CF airways will provide a
more physiologic comparison to non-CF airways by which to
base conclusions regarding primary defects in secreted mucin.
Purification and characterization oflarge molecular weight
mucus glycoprotein from xenografts. Purified large molecular
weight metabolically labeled mucin was analyzed from xeno-
grafts generated with 13 paired CF and non-CF bronchial tis-
sues. CF and non-CF-paired xenografts implanted within the
same mouse were simultaneously labeled with a mixture of
Na2S 3104 and [3H] glucosamine and secretions collected by irri-
gation. Crude secretions were purified through two rounds of
gel filtration which included digestion with hyaluronidase. Ad-
ditional studies evaluating the resistance of twice gel-filtration
purified mucin to Chondroitin ABC lyase and Heparin lyase
II demonstrate that Heparin/Heparan sulfate and Chondroitin/
Dermatan sulfate molecules are absent or minor contaminants in
these fractions (data not shown). Resistance of purified mucin
fractions to these enzymes was determined by the lack of move-
ment of radioactivity from the void volume to the included
volume peak using a third gel-filtration column after digestion.
Removal of contaminant proteoglycans and N-linked oligosac-
charides from mucin samples purified through a single round
of gel filtration was documented by two criteria including: (a)
the digestion of void volume large molecular weight glycopro-
tein fractions with hyaluronidase followed by fractionation of
a small molecular weight peak on a second gel-filtration column,
and (b) the removal of mannose binding lectin (GNA) material
from void volume peaks after reduction/carboxymethylation
and subsequent elution in the included volume peaks on a sec-
ond gel-filtration column.
Fig. 1 demonstrates the typical gel-filtration elution profile
of radiolabeled mucin from a CF and non-CF-paired sample.
The removal contaminant non-sulfated [3H] glucosamine-la-
beled molecules (likely proteoglycans) appears as smaller mo-
lecular weight peak (peak IUb, Fig. 1, C and D) after hyaluroni-
dase treatment of void volume fractions (Fig. 1, A and B, peak
Ia) from the first round of gel filtration. These studies have
reproduced the typical purification schemes of large molecular
weight mucus previously reported (25, 26, 28). Lectins were
also used to document the purification profile of mucin by evalu-
ating sialic acid (LFA lectin) and mannose (GNA lectin) bind-
ing. In these studies normalized dpm quantities of [3H] -
glucosamine-labeled mucus glycoprotein were slotted onto ni-
trocellulose and the filters probed with peroxidase-labeled
LFA- or GNA-labeled lectin. Filters were developed with DAB
and the intensity of the reaction products used to infer the extent
of lectin binding. To evaluate the purification of large molecular
weight mucin, the intensity ofLFA lectin binding was compared
with that of GNA for four fractions within the purification; (a)
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Figure 1. Purification of large molecular weight mucus glycoproteins by gel filtration. Paired CF and non-CF xenografts grafted within the same
mouse were metabolically labeled with 25 /Ci of both Na2S3504 and [3H]glucosamine for 72 hr and the radiolabeled secretions collected by
irrigation. Crude secretions were denatured in 8 M urea/DDT and eluted on a Sepharose CL-6B gel-filtration column (A, non-CF; B, CF). Void
volume fractions (Ia) were pooled, carboxymethylated, and digested with hyaluronidase and DNase. Hyaluronidase treated fractions were concentrated
to 500 IId and purified through a second round of gel-filtration (C, non-CF; D, CF). Void volume hyaluronidase insensitive fraction (Ib) and
hyaluronidase sensitive fractions (Ilb) were pooled for analysis. Comparisons of "5S/3H ratios were performed on fraction Ib. Samples at various
steps of the purification were compared for the extent of mannose and sialic acid content by lectin binding studies (E). In these studies peroxidase
linked lectins GNA (mannose binding) and LFA (sialic acid binding) were bound to 1000 dpm of the various fractions from a representative non-
CF sample slotted onto nitrocellulose filters. Crude secretions represent the starting material denatured in 8 M Urea/DDT. Pooled fractions (Ia)
were treated with hyaluronidase before lectin binding studies. Fractions Ib and fib were used directly following gel-filtration column chromatography.
Purified bovine submandibular gland mucus standard was purchased from Sigma Chemical Co. Results demonstrate the separation of mannose
containing glycoproteins (peak fib) from hyaluronidase insensitive large molecular weight mucin, (peak Ib).
crude secretions in 8 M urea; (b) the first gel-filtration void
volume peak (including all large molecular weight glycopro-
teins, peak Ta); (c) the second gel-filtration void volume peak
(including hyaluronidase insensitive large molecular weight
glycoproteins, peak Tb); and (d) the inclusion volume peak
from the second gel-filtration column (including hyaluronidase
sensitive small molecular weight glycoprotein fragments, peak
Ilb). Fig. 1 shows a typical lectin binding profile of fractions
of this purification scheme. These data demonstrate the increase
in LFA binding with successive purification steps and the disap-
pearance of GNA (mannose) binding lectin from the void vol-
ume peaks after carboxymethylation and hyaluronidase treat-
ment. These results provide evidence that both proteoglycan
and N-linked mannose containing oligosaccharide contaminants
were effectively removed by our purification strategy.
The molecular weight of purified large molecular weight
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Figure 2. Quantitation of [3H]glucosamine and S"O4 incorporation in
crude total secreted proteins and large molecular weight crude glycopro-
teins. To evaluate whether the total uptake of [3H]glucosamine and
S "04 molecules may be responsible for alteration in the extent of mucus
sulfation in CF airway epithelium, we quantitated the total radioactivity
in both crude urea dialyzed secretions and crude large molecular weight
void volume fractions from the first gel-filtration column (fraction Ia,
see Fig. 1). The graph shows the mean±SEM total dpms for each
fraction harvested from 13 independent CF and non-CF paired xeno-
grafts. The left axis gives the total [3H]glucosamine dpms while the
right axis gives the total S31O4 dpms. For comparison with purified
hyaluronidase treated large molecular weight mucin fractions given in
Fig. 3, the average ratio of S3 0O4 to [3H] glucosamine counts are given
above each group.
hyaluronidase insensitive mucus glycoprotein was determined
by gel-filtration with co-eluted molecular weight standards (Bi-
oRad Inc., Richmond, CA; myoglobin, 17 kD; ovalbumin, 44
kD; gamma globulin, 158 kD; thyroglobulin, 670 kD; and pro-
tein aggregates in excess of 5000 kD). These results demon-
strated a linear fractionation of molecular weight markers and
a co-elution of radioactivity of purified mucus glycoprotein with
large protein aggregate markers in excess of 5000 kD (data not
shown). From these studies we can conclude that the conditions
used for gel-filtration purification in this study isolate mucin in
excess of 5 million dalton molecular weight.
To address whether alterations in the extent of sulfation may
be due to variable uptake of radiolabeled precursors Na2S3504
or [3H]glucosamine between CF and non-CF epithelium, we
assessed the total 35S and 3H dpm counts in both crude urea
dialyzed total secretions and partially purified large molecular
weight glycoproteins from the first gel-filtration column (peak
Ia, see Fig. 1). Results from this analysis are presented in
Fig. 2 and demonstrate no significant differences in the total
incorporation of [3H]glucosamine within either crude or peak
Ta fractions between CF and non-CF. Furthermore, although the
[3H]glucosamine normalized level of 35S incorporation tended
to be higher for CF xenografts (1.2-fold for crude secretions,
and 1.3-fold for peak Ia), the extent of this increase was less
than that seen following hyaluronidase treatment (results dis-
cussed below). These findings suggest that alterations in the
extent of [3H]glucosamine uptake do not confound analyses
which normalize the extent of sulfation to [3H] glucosamine
incorporation.
Sulfate content of mucus glycoprotein from CF and non-
CF xenografts. To avoid differences in the specific activity of
radiolabeled precursor and variability in the extent of precursor
incorporation between experiments, only matched xenografts




















Figure 3. Radiolabeled sulfur content of purified hyaluronidase insensi-
tive large molecular weight mucus glycoprotein from CF and non-CF
xenografts. The IS/[3H]glucosamine ratio of purified large molecular
weight mucus glycoprotein was compared from xenografts generated
from 13 independent CF and non-CF paired tissues. When duplicate
xenografts were performed from one set of tissue samples, the raw 35S/
[3H ] glucosamine ratios were averaged. For presentation, the 35S/[3H] -
glucosamine ratio was normalized for each pair of CF and non-CF
xenografts such that the non-CF sample was made equal to one. This
was necessary due to variability in the absolute labeling efficiency be-
tween experiments performed on different days. This was in part due
to variability in the specific activity of Na2S3504 and [3H] glucosamine
precursor from different lots. The cumulative data is presented from all
CF and non-CF paired samples with two subdivided CF categories based
on genotype (group-A, known genotype on both alleles [a listing of
individual genotypes and normalized 35S/[3H]glucosamine ratios are
given in Table I]; group-B, partially defined genotypes including two
patients with AF508/unknown and one patient with G551D/unknown
genotypes). Groups were analyzed for statistically significant differ-
ences by a paired analysis of the raw 35S/[3H] glucosamine ratios using
Student's t test. The following p-values were obtained: (a) all CF sam-
ples vs non-CF, P < 0.026, n = 13; (b) CF group-A vs non-CF, P
< 0.004, n = 10; (c) CF group-B vs non-CF, P > 0.95, n = 3.
compared the sulfation ratios between CF and non-CF purified
large molecular weight, hyaluronidase insensitive, mucus glyco-
protein by several criteria. All statistical comparisons were per-
formed by a paired Student's t test analysis of the raw 35S/
[3H] glucosamine ratios. When 35S/[3H] glucosamine ratios
were compared between all CF and non-CF samples the mean
increase in sulfation was 1.7±0.18-fold higher (P < 0.026, n
= 13) in CF as compared with non-CF samples (Fig. 3 and
Table I). However, when the genotypes of the various CF sam-
ples were tabulated, two categories emerged which showed dif-
ferences in their sulfation profile. The first of these categories
involved CF samples with definable genotypes [AF508/AF508
(n = 4); AF508/1717 (n = 2); AF508/621 (n = 2); G542X/
G551D (n = 1); AF508/G542X (n = 1)] which showed a
2.0±0.15-fold higher 35S/[3H]glucosamine ratio (P < 0.004)
as compared with non-CF samples (Fig. 3). The average raw
35S/[3H]glucosamine ratios for this CF category was 0.32±0.07
as compared with 0.16+0.04 for the non-CF samples. When
the fold increase in 35S/[3HH] glucosamine ratios were compared
between these various known CF genotypes, no statistical differ-











Table L CF Patient Clinical Information
Age* Sex CF genotype* PS/PI§ Sweat Cl"1 35S/[3H] ratio
37 M AF508/AF508 PI N/A 2.2
22 M AF508/AF508 PI 93 1.8
13 M AF508/AF508 PI 117 0.78
24 M AF508/hF508 PI 112 2.1
22 F AF508/1717-1G>A PI 120 2.0
34 F AF508/1717-1G>A PI 85 2.6
31 M AF508/G542X PI 82 1.8
17 F G542X/G551D PI 93 1.9
27 M AF508/621 + 1G>T PI 125 2.5
27 M zAF508/621 + 1G>T PI 69 2.0
34 F G55ID/? PI 108 0.46
34 M AF508/? PI 78 1.2
23 M AF508/? PI 87 0.93
* The age at which CF patients underwent lung transplantation. I Ques-
tion mark denotes unknown mutant alleles (genotypes screened include
G85E, R117H, 621+1G>T, R334W, R347C, R347P, R347H, S492F,
Q493R, 1609delCA, A1507, LF508, 1717-lG>A, G542X, S549I,
S549N, S549R (A>C), GSSlD, R553X, R506T, R1162X, S1251N,
W1282X, R1283M, R1283K, and N1303K. § PS, pancreatic sufficient;
PI, pancreatic insufficient. N/A, sweat chloride not available. I Ratio
of 35S/[3H]glucosamine from CF xenograft purified mucin normalized
to paired controlled non-CF mucin.
ences were seen (Fig. 3 and Table I). Surprisingly, a second
category of CF samples with only partially defined genotypes
[AF508/unknown (n = 2) and G551D/unknown (n = 1)]
showed no statistical difference in the extent of sulfation as
compared to their matched non-CF controls (Fig. 3 and Ta-
ble I).
Discussion
The identification of biochemical defects in mucus glycoprotein
have been suggested to play a pathophysiologic relevant role
in CF lung disease. Although evidence to support this claim
remains controversial, such defects have been hypothesized to
potentially enhance the ability of bacteria to colonize the CF
airways. The fundamental hypothesis of intracellular glycopro-
tein processing defects stems from previous studies which have
demonstrated an altered pH within golgi compartments of CF
as compared with non-CF cells. In this model, defective CFTR
is thought to hinder the acidification of the golgi by a H+ -
ATPase through an increased electrochemical gradient brought
about by the lack of CFTR mediated Cl - flow into this vesicular
compartment. This increase in pH is thought to decrease the
activity of golgi modifying enzymes such as sialyltransferases
which intern provide more assessable sites for sulfation. Hence,
the extent of sulfation provides a useful marker for evaluation of
intracellular processing defects in glycoprotein such as mucin.
Previous studies evaluating both native and explant pro-
duced mucus from CF and chronic bronchitic patients have
compared the extent of mucus sulfation as an endpoint for gly-
coprotein processing defects. Several studies have reported a
2-3-fold higher level of sulfation together with deceased levels
of sialylation in CF airway mucus (26) while others have found
no data to support this claim (30). The etiology of differences
reported between laboratories presently remains unexplained.
We hypothesized that these discrepancies in the literature may
be due to differences in CF genotype. Hence, using the level
of mucous sulfation as a surrogate endpoint for intracellular
glycoprotein processing defects, we sought to perform a com-
prehensive survey of mucus glycoprotein sulfation from 13 in-
dependent CF samples encompassing seven different mutant
CFTR alleles. The human bronchial xenograft was chosen as
the model of choice for several reasons including: (a) the ab-
sence of secondary effects caused by chronic bacterial infection,
(b) its in vivo relevance as a differentiated mucociliary airway
epithelium, and (c) the ability to generate genetically defined
CF and non-CF airway epithelium.
The effect of airway remodeling (i.e., goblet cell hyperpla-
sia) due to chronic bacterial infection in CF has provided the
largest debated obstacle in evaluating the properties of secreted
mucin and may be responsible for many of the conflicting re-
ports evaluating primary defects. Such secondary effects of in-
fection are thought to effect the properties of secreted and mem-
brane bound glycoproteins. To this end, we hypothesized that
culturing of CF primary airway epithelial progenitors followed
by regeneration of an intact fully differentiated epithelium might
provide a more "normal" distribution of airway epithelial cells.
In support of this hypothesis is a recently reported study which
evaluated the clonal expansion of progenitor cell clones in hu-
man bronchial xenografts using retroviral histochemical mark-
ers (33). This study, which used in vitro retrovirally infected
primary human airway epithelial cells to reconstitute human
bronchial xenografts, found that clones composed of goblet cells
alone were absent from the reconstituted epithelium. Although
these findings do not discount the possibility that goblet cells
may be capable of replicating in vivo, these studies demonstrate
that goblet cells are not capable of proliferating as progenitor
cells in vitro under the conditions described in the present study.
Hence we hypothesized that the higher percentage of goblet
cells in the initial population of isolated epithelial cells would
not contribute to progenitor cells which expand in vivo within
xenograft epithelium. This hypothesis assumes that, in the ab-
sence of infection, CF airway epithelial progenitor cells would
give rise to normal airway architecture. To test this hypothesis,
we evaluated the percentage of goblet cells within fully differen-
tiated CF and non-CF xenografts using morphologic techniques
of histochemical staining. These studies demonstrated no statis-
tically significant difference in the percentage of alcian blue
positive goblet cells between CF and non-CF xenografts. Such
findings support the hypothesis that goblet cell hyperplasia in
CF is an environmentally phenomena stimulated by chronic
bacterial infection and not a primary defect caused by defective
CFTR function. Additionally, the fact that the total yields of
[3H] glucosamine labeled large molecular weight purified mucin
were not statistically different between CF and non-CF xeno-
grafts substantiates findings which demonstrate a similar abun-
dance of goblet cell (data not shown). These results support
the utility of the xenograft model system for studying primary
defects in mucus not hindered by secondary effects of infected
airways.
Large molecular weight radiolabeled mucus glycoprotein was
purified through two rounds of denaturing gel-filtration. As an
indicator of mucous processing defect, the extent of radiolabeled
35S incorporation was compared as the ration to [3H] glucosamine
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between 13 paired CF and non-CF control tissues. Of the seven
different genotypes analyzed, CF xenografts demonstrated a
1.7+0.18-fold higher (n = 13, P < 0.026) level of sulfation
as compared with non-CF controls. These data substantiate the
findings by other investigators which have demonstrated from
both in vivo bronchial secretion and in vitro explants a 2-3-
fold higher level of sulfation. However, further classification of
mucous sulfation patterns with respect to 26 screened genotypes
demonstrated two categories of CF samples. The first of these
categories included CF samples with defined genotypes including
[AF508/AF508 (n = 4); AF508/1717 (n = 2); AF508/621
(n = 2); G542X/G551D (n = 1); AF508/G542X (n = 1)].
No differences in the level of sulfation were seen within these
genotypes which cumulatively demonstrated a mean increase in
the 35S/[3H]glucosamine ratio of 2.0+0.15-fold (n = 10, P <
0.004). Interestingly, the CF samples which did not demonstrate
an increase in sulfation had one unidentified allele [AF508/un-
known (n = 2) and G551D/unknown (n = 1)]. This genotype
grouping may in part explain some of the discrepancies in study-
ing sialylation and sulfation in CF secreted mucus in the litera-
ture. All CF patients where clinically diagnosed with CF and
received lung transplantation as therapy. Several clinical aspects,
including age at which transplantation was performed and sweat
chlorides, were compared with gain insight into the severity of
disease and extent of glycoprotein processing defects. No correla-
tion with the extent of mucous sulfation was seen with either of
these two criteria. Furthermore, the extent of lung disease in all
CF patients was classified as severe and implies that sulfation of
mucus glycoprotein may not be pathophysiologically significant
in the progression of lung disease.
The variability in mucous sulfation found between two geno-
typically defined groups of CF patients at present remains unex-
plained. However, two current hypotheses are consistent with the
findings in this report. First, because of the small numbers of
patients with undefined mutant allele(s) which showed no in-
crease in sulfation, these results may be due to variability within
the CF population potentially caused by modifying genes. In
support of this argument is the one AF508/AF508 patient which
showed no increase in the level of mucous sulfation (Table I).
This finding which demonstrates some level of variability within
a defined genotype group, suggests that factor(s) not related to
CFTR function may affect mucous sulfation. These factors could
simply result from variability within the xenograft model system
or may implicate the involvement of other genes in mucus glyco-
protein processing. A second more interesting speculation may
be that an as yet unidentified mutant allele( s), in the patients with
partially defined genotypes, provides some level of functional
intracellular CFTR capable of facilitating normal mucus glyco-
protein processing. This undefined mutant allele was not found
within a comprehensive screen of the 26 common CF genotypes.
Despite the cause of variability in mucous sulfation between CF
patients, these studies support previous findings which implicate
CFTR functional involvement in mucus glycoprotein processing.
The correlation of this defect with CF genotype has provided a
more comprehensive look at the complexities by which CFT1R
may effect this potentially pathophysiologic process.
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